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Humanpapillomavirus(HPV)L1virus-likeparticles(VLPs)wereprovenaneﬀectivevaccinecandidatetopreventagainstHPV-16
and -18 infections. In order to evaluate the potency of our produced HPV-16 and -18 L1 VLPs-based vaccine candidates, also to
quantify neutralizing antibodies induced by them, a 2-plex Luminex-based competitive immunoassay was developed. Unlike the
published paper, the no-biotin conjugated neutralizing mAbs spiked normal human serum (NHS) was used for standard curve
preparation, while phycoerythrin (PE) was not labeled directly to neutralizing mAbs for signaling. After the coupling optimization
of VLPs to microspheres and the neutralizing mAbs biotinylation, the 2-plex standard curve was prepared with good ﬁt and high
dynamic range. In addition, no cross-reactivity was also conﬁrmed. The 2-plex Luminex-based immunoassay represents good
potential not only for vaccine candidate’s evaluation but also for its further clinical use.
1.Introduction
Cervical canceris the second most frequentcancerin women
in the world, comprising about 10% of all human cancers
[1]. A current summary report from WHO indicates that
thereareabout500thousandwomendiagnosedwithcervical
cancer, of whom about 270 thousand women die from the
diseaseeveryyear[2].InChina,atotalof500millionwomen
are at risk of cervical cancer [3].
After more than 30 years of research into the infectious
nature of cervical cancer, it is well established that human
papillomaviruses (HPVs) are the primary cause for cervical
cancer [4]. Nearly all cervical cancer cases are linked to
genital infection with HPVs. Up till now, over 130 diﬀerent
types of HPV have been found, where HPV-16 and HPV-
18 are of high risk, contribute to over 70% of all cervical
cancer cases [5]. Therefore, prevention of HPV-16 and HPV-
18’s infection among women becomes an important issue
for scientists and epidemiologists to lower the incidence of
cervical cancer.
HPVsaredouble-strandedDNAviruses,whichtargetthe
basal cells of squamous epithelia for infection [6]. The struc-
ture of its circular DNA genome are composed of 2 major
oncogenes E6 and E7, 2 major structural protein genes L1
and L2 [7]. Based on these elements, diﬀerent vaccines have
been developed or are under development. The L1 protein
of HPV expressed recombinantly in vitro can self-assemble
intovirus-likeparticles(VLPs).VLPshaveHPVtype-speciﬁc
conformational neutralizing epitopes and thus induce type-
speciﬁc neutralizing antibodies to protect against HPV
infections [8]. In line with this fact, large pharmaceutical
companies like Merck and GSK have developed VLP-based
vaccine products and successfully put them into the market,
using yeast and insect cell expression systems, respectively
[1].BothofthesetwoproductsincludeVLPsforHPV-16and
HPV-18. In our company, an L1 VLP-based vaccine candi-
date aiming at HPV-16 and HPV-18 was also produced using
yeast protein expression system [9, 10]. It includes VLP-16
and VLP-18 and thus should prevent against over 70% of
cervical cancers. For L1 VLP-based vaccines, the eﬃcacy is2 Journal of Biomedicine and Biotechnology
largely dependent on the number of neutralizing antibodies
inducedby the conformational neutralizing epitopes existing
on VLP surfaces. The more the neutralizing antibodies are
induced, the more the vaccine should be eﬀective to protect
against HPV infections.
To date, diﬀerent methods have been developed to quan-
titate the type-speciﬁc neutralizing antibodies for HPVs,
such as pseudoneutralization assays [11] and cRIAs [12].
All these methods have limitations as being time consuming
or less sensitive. For this reason, several studies have used
a Luminex-based competitive immunoassay [13, 14]w h i c h
could be used to quantify diﬀerent type-speciﬁc neutraliz-
ing antibodies in a single reaction simultaneously. In the
assay, diﬀerent types of VLPs were bound with diﬀerent
kinds of microspheres, then the known, HPV type-speciﬁc,
phycoerythrin-labeled neutralizing monoclonal antibodies
(mAbs) were mixed with VLP-coupled microspheres and
the vaccine challenged serum samples for reaction, where
the PE-labeled neutralizing mAbs compete with the serum
antibodies to bind to the conformational epitopes on VLPs.
After that, the microspheres were put into Luminex systems
for detection of the PE signal. Therefore, strong signals mean
more PE-labeled mAbs binding, and thus less neutralizing
antibodies existed in the serum sample. In order to quan-
titatively evaluate the high and low levels of neutralizing
antibodies, reference standards are essential. Serum from
African green monkeys hyperimmunized with HPV L1 VLPs
was reported [14] to be used as reference standards success-
fully. An alternative is to make use of normal human serum
spiked with unlabeled type-speciﬁc neutralizing monoclonal
antibodies as reference standards.
Inthisstudy,a2-plexLuminex-basedcompetitiveimmu-
noassay was developed to evaluate the eﬃcacy of our HPV-
16 and HPV-18 L1 VLP-derived vaccine candidates. The
reference standard was prepared using normal human serum
spiked with various amounts of no-ﬂuorescence labeled
type-speciﬁc neutralizing mAbs rather than HPV-positive
serum. The ﬂuorescence-labeled neutralizing mAbs were
not coupled directly with PE but with biotin ﬁrst, and an
amount of streptavidin-PE was added then for detection,
which makes the assay more ﬂexible. In developing the assay,
at ﬁrst, the coupling ratio of VLPs to microspheres and the
coupling ratio of biotin to type-speciﬁc neutralizing mAbs
were optimized, the mixed VLP-coupled microspheres were
blended with the mixed biotinylated neutralizing mAbs to
conﬁrm the lack of cross-neutralizing activity, and ﬁnally
a 2-plex standard curve for the competitive immunoassay
wasconstructedforneutralizingantibodydetectioninserum
samples.
2.MaterialsandMethods
2.1. Reagents and Equipment. In this study, the microspheres
Bio-Plex COOH Bead 038 and Bio-Plex COOH Bead 053
were purchased from Bio-Rad Corporation, Hercules, Calif.
T h eH P V - 1 6L 1V L Pa n dH P V - 1 8L 1V L Pw e r ep r o d u c e d
by yeast protein expression system in the laboratory of
Shanghai Zerun Biotechnology Co., Ltd. Shanghai, China.
The neutralizing monoclonal antibodies (mAbs) H16.V5
for HPV-16 and H18.J4 for HPV-18 were kindly provided
by Dr. Neil Christensen, Penn State University, Penn State,
USA. The normal human serum was purchased from a local
hospital, Shanghai, China.
The Luminex 200 system was purchased from Luminex
Corporation, and data was collected and analyzed with
Luminex IS 2.3 and Prism 4. Microspheres were incubated
in 96-well 1.2µm PVDF ﬁlter microtiter plates (Millipore,
Billerica, Mass) and rotated in MS 3 digital (IKA, Janke &
Kunkel-Str. 10 D-79219 Staufen, Germany). The washing
steps were carried out in Bio-Plex Pro II Wash Station (Bio-
Rad, Hercules, Calif).
2.2. Coupling of HPV L1 VLPs to Microspheres. VLPs were
coupled to microspheres according to the previously pub-
lished methods with a few modiﬁcations [13, 14]. HPV-16
L1 VLP (VLP-16) and HPV-18 L1 VLP (VLP-18) were cova-
lently conjugated to Bio-Plex COOH Bead 038 (#38 beads)
and Bio-Plex COOH Bead 053 (#53 beads), respectively, as
follows.
Initially carboxylated beads (1.25 × 107 beads/mL) were
fully suspended by vortexing and sonication, and then
about 500µL beads were transferred to a 1.5mL Protein
LoBind Tube (Eppendorf) for coupling. After centrifuging
the tube at 14000g for 4min, the supernatant was removed.
Then the beads were washed once with 500µL0 . 1 M
NaH2PO4 (pH 6.2) by vortexing and sonication, followed
by an incubation with 50µL 50mg/mL sulfo-NHS (Pierce,
Rockford, IL), 70µL 0.4M 1-ethyl-3-[3-dimethylamino-
propyl]carbodiimide hydrochloride (EDC) (GE, Shanghai,
China), and 380µL PBS (pH 7.4) for activation, where
amine-reactive esters of carboxylate groups were formed for
labeling.Theactivationlastedindarknessfor30min,at800–
1000rpm, RT. After that, the beads were washed twice with
50mM MES buﬀer (Sigma, pH 6.0) and pelleted in MES
buﬀer before counting using a hemocytometer.
TheHPVL1VLPsweretransferredto50mMMESbuﬀer
(pH 6.0) by ultraﬁltration, and then its concentration was
determinedbyBCA(BCAproteinassaykit,Pierce,Rockford,
Ill) before use.
In coupling, 1 × 105 activated beads and buﬀer with
transferred VLPs were mixed in MES buﬀer to a ﬁnal volume
of 100µL–200µL. The mixture was rotated in darkness, at
800–1000rpm, RT, overnight. Consequently, the beads were
washed twice with PBS plus 0.05% Tween-20 (pH 7.4),
followed by blocking in histidine buﬀer (20mM histidine
(Sigma), 0.5M NaCl, 1%BSA, pH 6.2) for 30min in dark-
ness, RT, at 800–1000rpm. After washing the beads twice
with histidine buﬀer, they were counted by hemocytometer
and diluted to 1 × 106 beads/mL in histidine buﬀer for
preservation in darkness, at 4◦C.
2.3. Neutralizing mAbs Biotinylation. The HPV-16 and HPV-
18 neutralizing mAbs H16.V5 and H18.J4 were biotinylated
using Micro Sulfo-NHS-LC-Biotinylation Kit (Pierce). The
procedure followed the manufacturer’s instructions. In brief,
neutralizing monoclonal mAbs were transferred to PBS
(pH 7.2–7.4) and subjected to BCA (BCA protein assayJournal of Biomedicine and Biotechnology 3
kit, Pierce) to determine concentration before biotinylation.
An amount of active Sulfo-NHS-LC-Biotin for diﬀerent
mole ratios of biotin and mAb was then added, and the
mixture was rotated at 800–1000rpm in darkness, RT, for
45min. Finally, the biotinylated beads were put at −20◦C
immediately to stop the reaction and stored before use.
2.4. Conﬁrming the Neutralizing mAbs Biotinylation. The
biotinylation of H16.V5 and H18.J4 was conﬁrmed to
determine the optimal mole ratio of biotin and mAbs for
reaction.Theprocesswasdescribedasfollows.Inaprewetted
96-well microtiter ﬁlter plate, 5000 VLP-16 conjugated #38
beads (25µL, 2 × 105 beads/mL, Coupling ratio = 40µg
protein per million beads) or VLP-18 conjugated #53 beads
(25µL, 2×105 beads/mL, Coupling ratio = 40µgp r o t e i np e r
million beads) were mixed with 25µL of diluted biotinylated
H16.V5 (Biotin/H16.V5 mole ratio = 20/1, 40/1, 80/1, 160/1,
320/1, 640/1, 1280/1) or biotinylated H18.J4 (Biotin/H16.V5
mole ratio = 20/1, 40/1, 80/1, 160/1, 320/1, 640/1, 1280/1)
and 50µL PBS-BSA to a ﬁnal volume of 100µL, where the
biotinylated mAbs were 20-fold diluted, followed by a 2-fold
serious dilution in a total of 11 diﬀerent dilutions. Then the
microtiter plate was rotated at 800–1000rpm, in darkness,
for 3h, followed by 3 times of wash in Wash Station.
After that, 50µL2 . 5 µg/mL streptavidin-PE was added for
incubation at 800–1000rpm, in darkness, for 20min. The
beads were then washed 3 times and resuspended in 125µL
PBS-BSA for reading in Luminex 200 system (Luminex
Corporation, Austin, Tex).
2.5.ConﬁrmingtheCouplingofHPVL1VLPstoMicrospheres.
After the coupling reaction of HPV L1 VLPs to microspheres
has been completed, the coupling eﬃciency was conﬁrmed.
In brief, 5000 VLP-16 conjugated #38 beads (25µL, 2 ×
105 beads/mL) or VLP-18 conjugated #53 beads (25µL, 2 ×
105 beads/mL) were mixed with 25µL biotinylated H16.V5
(Biotin/H16.V5 mole ratio = 100/1) or biotinylated H18.J4
(Biotin/H18.J4 mole ratio = 100/1) and 50µL PBS-BSA
buﬀer (PBS, 1% BSA, pH 7.4) to a ﬁnal volume of 100µL, for
incubation in a 96-well prewetted ﬁlter plate, in darkness, at
800–1000rpm for 3h, where the biotinylated mAb was 1:50,
1:100, 1:1000 diluted in PBS-BSA buﬀer (PBS, 1% BSA,
pH 7.4). Then the beads were washed 3 times in Bio-Plex
Pro II Wash Station (Bio-Rad) using PBS-BSA buﬀer. After
that,50µL2.5µg/mLstreptavidin-PEwasadded,followedby
incubation in darkness, at 800–1000rpm for 20min. After
washing the beads again for 3 times with the Wash Station,
125µL PBS-BSA buﬀer was added for reading in Luminex
200 system (Luminex Corporation). All assays were made in
triplicates.
2.6. 2-Plex Standard Curve Preparation for Competitive Im-
munoassay. In this study, the normal human serum spiked
with diﬀerent amounts of the no-biotin labeled neutralizing
mAbs was used as the standard. It was prepared as follows:
initially the normal human serum (NHS) was blended with
certain amounts of unlabeled H16.V5 and H18.J4 to a
ﬁnal concentration of 20µg/mL. Then, the mixture was
2-fold diluted with NHS to make H16.V5 and H18.J4 in a
series of 15 diﬀerent concentrations. For each 50µL diluted
sample, 5000 VLP-16 conjugated #38 beads (Coupling ratio
= 40µg protein per million beads), 5000 VLP-18 conjugated
#53 beads (Coupling ratio = 40µg protein per million
beads), 500-fold diluted (ﬁnal dilution) biotinylated H16.V5
(Biotin/H16.V5 mole ratio = 320/1), and 200-fold diluted
(ﬁnal dilution) biotinylated H18.J4 (Biotin/H18.J4 mole
ratio = 640/1) were added to a ﬁnal volume of 100µL,
followed by an incubation in 96-well prewetted ﬁlter plate, in
darkness, at 800–1000rpm for3h. Afterwashing in triplicate
by Wash Station using PBS-BSA buﬀer, the beads were added
with 50µL2 . 5 µg/mL streptavidin-PE and rotated at 800–
1000rpm, in darkness, for 20min for staining. Finally the
beads were washed again in triplicates and resuspended
in 125µL PBS-BSA buﬀer before reading in Luminex 200
system (Luminex Corporation). All assays were conducted in
duplicates.
2.7. Cross-Reactivity. In brief, 5000 VLP-16 conjugated #38
beads (Coupling ratio = 40µg protein per million beads)
and 5000 VLP-18 conjugated #53 beads (Coupling ratio =
40µg protein per million beads) were added with 40-fold
diluted (ﬁnal dilution) biotinylated H16.V5 (Biotin/H16.V5
mole ratio = 320/1) and 200-fold diluted (ﬁnal dilution)
biotinylated H18.J4 (Biotin/H18.J4 mole ratio = 320/1) or
both. All assays were conducted in duplicate.
3. Results
3.1. Determine the Optimal Coupling Ratio of HPV L1 VLPs
to Microspheres. Diﬀerent ratios (µg/million beads) of HPV-
16 L1 VLP or HPV-18 L1 VLP and #38 or #53 microspheres
wereusedforcoupling,respectively.TheVLPcoupledmicro-
spheres were then reacted with the same amount of related
neutralizing mAbs. The coupling ratio at which the VLP-
conjugated beads can generate the strongest signal was then
selected as the optimal. Diﬀerent dilutions of neutralizing
mAbs led to the same results. The coupling reaction for VLP-
16 and #38 beads was saturated when coupling ratio was big-
ger than 40µg protein per million beads (Figure 1(a)), while
for VLP-18 the optimal coupling ratio was 40µgp r o t e i np e r
million beads (Figure 1(b)). The results may be due to their
speciﬁc dimensional structures and diﬀerent neutralizing
epitopes. Another concern for choosing 40µgp r o t e i np e r
million beads was to ﬁnd a robust way for coupling; more
VLPs used could ascertain the same quality of coupled beads
at each time. It would be important in QC and clinical trial.
3.2. Determine the Optimal Coupling Ratio for Neutralizing
mAbs Biotinylation. For biotinylation of neutralizing mAbs
H16.V5 and H18.J4, diﬀerent coupling mole ratios of amine
reactive biotin and mAb were tried, and the biotinylated
mAbs were then mixed with VLP-conjugated microspheres
for reaction. The optimal coupling mole ratio was the one
at which the reaction could generate the strongest signal.
For both H16.V5 and H18.J4, the optimal coupling ratios of
biotin to mAbs were 320/1 or higher (Figures 2(a) and 2(b)),4 Journal of Biomedicine and Biotechnology
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Figure 1: Coupling ratio optimization for HPV L1 VLPs and
microspheres. (a) HPV-16 L1 VLP and #38 microspheres. (b) HPV-
18 L1 VLP and #53 microspheres.
where the biotinylation reaction was saturated at the current
detection system. When changing our system, for example,
the added amount and concentration of streptavidin-PE, the
optimal coupling ratio for biotinylation may be higher, be-
cause there may be not enough streptavidin-PE for staining.
3.3. No Cross-Reactivity. Before mixing the 2 VLP-conju-
gated microspheres together for immunoassay, studies were
carried out to make sure that no cross-reactivity existed
between the 2 analytes. Just as predicted, with our produced
HPV vaccine candidates, biotinylated H16.V5 could only
bound to VLP-16 coupled microspheres for signaling while
biotinylated H18.J4 only bound to VLP-18 coupled micro-
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Figure 2: Coupling ratio optimization for neutralizing mAbs
biotinylation. (a) H16.V5 biotinylation. (b) H18.J4 biotinylation.
spheres (Figure 3). The results ascertained the establishment
of the 2-plex immunoassay with high sensitivity and speci-
ﬁcity. In this section, the saturated VLP coupled beads plus
the saturated biotin coupled mAb just generate no cross-
reactivity.
3.4. 2-Plex Standard Curve Preparation for the Luminex-
Based Competitive Immunoassay. The optimized conditions
were adopted for standard curve (STD) preparation. The
c o u p l i n gr a t i o sf o rV L P st om i c r o s p h e r e sw e r eb o t h4 0 µg
protein per million beads. The biotinylation ratios for biotin
to neutralizing mAbs were 320/1 or higher. Not surpris-
ingly, standard curve preparations (Figure 4) for the 2-plex
Luminex-based competitive immunoassay were established
successfully with good ﬁt (R2 > 0.99) for both analytes and
wide dynamic range (9.8ng/mL to 5.0µg/mL for VLP-16
neutralizing antibodies, while 39.0ng/mL to 5.0µg/mL forJournal of Biomedicine and Biotechnology 5
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Figure 3: Cross-neutralizing reactivity investigation.
VLP-18 neutralizing antibodies), where the no-biotinylated
mAbs (standards) and biotinylated mAbs competitively bind
to HPV VLP coupled microspheres.
4. Discussion
Luminex xMAP system is a technology combined with ﬂow
cytometry, microspheres, and lasers together, which allows
the quantitation of up to 100 diﬀerent analytes simultane-
ously using quite small sample volumes in a single reaction
[15]. It has been applied to HINI detection [16], kidney bi-
omarkers detection [17], human leukocyte antigen genoty-
ping [18], cytokine detection and quantitation [19], and so
forth. with high sensitivity and speciﬁcity.
Cervical cancer, as the second prevalent cancer in women
in the world, was caused by HPV infections. Some studies
have revealed that HPV L1 VLP-based vaccine could eﬀec-
tively induce type-speciﬁc neutralizing antibodies to HPVs
and thus protect against their invasions [1]. In order to make
the vaccine more powerful, it was often designed to target
more than one type of HPVs, for instance, Merck’s Gardasil
aimed at HPV-6, -11, -16, and -18 simultaneously. As a
sensitive, economic and high-throughput method, Luminex
system was reported [13, 14] to evaluate the eﬃcacy of
the HPV L1 VLP-based vaccine products. Compared to the
traditional ELISA- or FACS-based method, Luminex has
many advantages. It could be used to quantitate type-speciﬁc
neutralizing antibodies induced by various HPVs simultane-
ouslyandthuswasmorepracticalforclinicaluse,wherelarge
numberofserumsamplesshouldbeanalysedinashorttime.
Here, in order to establish an assay for eﬃcacy determination
of our HPV-16, -18 L1 VLPs based vaccine candidate, also
for further clinical use, a 2-plex Luminex-based competitive
immunoassay was also developed. Although the reported
method represents an important reference for this study,
some modiﬁcations were tried to make the assay more ﬂex-
ible in the practical use.
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Figure 4: 2-plex standard curve for the Luminex-based immunoas-
say.
When developing the immunoassay, ﬁrst of all, the
amount of VLP needed for coupling with microsphere
should be determined to generate constant and strong sig-
nals. For the 2-plex method, 2 diﬀerent beads were prepared
for HPV-16 L1 VLP and HPV-18 L2 VLP, respectively.
Interestingly, the optimal coupling ratio for VLP-18 was
40µg/million beads, while for VLP-16 the coupling would
be saturated if the ratio was bigger than 40µg/million beads,
which may be due to the diﬀerent neutralizing epitopes
existed in VLP-16 and VLP-18. On the other hand, in this
step, it was also found that low-binding tube was very
essential for coupling of high quality (data not shown), while
the conventional tube may absorb microspheres during the
reaction and thus lower the recovery.
The amount of biotin needed for biotinylation of neu-
tralizing mAbs should also be optimized. In the reported
method, the signal dye PE was bound directly to mAbs,
which we thought was inﬂexible for the assay’s practical
use. Sometimes, it is diﬃcult to obtain a stable PE labeled
mAb or other molecules when several new analytes are to
be added to this multiplex assay. In contrast, biotin labeling
technology is highly developed, and it is simple to obtain
stable biotinylated mAb. In fact, biotinylated mAb plus
streptavidin-PE was commonly used for signaling in most
ELISA, Luminex, or other immunoassay-based systems. In
this study, the optimal ratios for biotinylation of H16.V5 and
H18.J4 were determined, respectively.
Just as predicted, with our produced HPV-16 and
HPV-18 L1 VLPs based vaccine candidate, no cross-activity
was found between H16.V5 and H18.J4, which were well-
characterized, strong type-speciﬁc HPV-16 and HPV-18
neutralizers. After that, the 2-plex standard curve (STD)
of the competitive immunoassay for quantifying antibodies
neutralizing HPV-16 and HPV-18 simultaneously was then
tried to be constructed. Unlike the published paper from
Merck, normal human serum spiked with no biotin labeled
neutralizing mAbs was used for standards, instead of VLP6 Journal of Biomedicine and Biotechnology
challenged monkey serum. The major reason for that is the
diﬃculty in preparing enough well-characterized and stan-
dardized serum for the assay. In this study, the 2-plex STD
for HPV-16 and HPV-18 was well established with high
sensitivity and wide dynamic range. Later the assay was tried
to measure the induced neutralizing antibodies in VLP chal-
lenged mice serum. It could be distinguished with diﬀerent
antibody levels for HPV-16 and HPV-18 simultaneously, of
samples derived from mice challenged with our developed
VLP vaccine candidate of diﬀerent doses (data not shown).
Therefore, the 2-plex Luminex-based assay provided a fast,
sensitive, and eﬀective approach to evaluate the eﬃcacy of
our HPV L1 VLP-based vaccine candidate.
At present, the dilution buﬀer used for assay was normal
human serum for clinical sample use. When applying the
assaytomonkeyormouseserumsamples,thedilutionbuﬀer
should better use normal monkey serum or normal mouse
serum accordingly because it is commonly used as the dilu-
tion matrix or blank. The published paper suggests the use of
antibody-depleted human serum (ADHS) as dilution buﬀer
because of its reliable and stable resources, which we thought
could also be tried in our developed systems in the future. In
addition, “the unit” used for characterizing the level of neu-
tralizing antibodies in serum samples should be deﬁned. In
doing this, large number of serum samples with neutralizing
antibodies oflow,medium,andhighlevelsshouldbeapplied
to the same STD curve, to further validate the assay.
5. Conclusions
A 2-plex Luminex-based competitive immunoassay was
developed to evaluate the eﬃcacy of our HPV L1 VLP-based
vaccinecandidateininducingneutralizingantibodiesagainst
HPV-16andHPV-18.Somesmallbutessentialmodiﬁcations
have been made, compared to the reported publications.
The assay was convenient, sensitive, eﬀective, and requiring
only small amount of samples. Recently, additional studies
from our laboratory are underway to further validate the
assay and also determine the method limitation with plenty
of serum samples. The correlations of the assay to other
characterization method for HPV L1 VLP-based vaccines
like pseudoneutralization assay [11]a n dI V R P[ 20]w e r e
also investigated. Moving forward, as researches on the assay
become more comprehensive, the 2-plex Luminex assay
will be routinely applied for evaluating and quantifying
neutralizing antibodies in clinical use.
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